Why Insmed (INSM) Stock Is Plunging Today

NEW YORK (TheStreet) -- Insmed  (INSM) plunged Monday after the company announced it would conduct two Phase III studies of its lead drug candidate Arikayce, which indicates a delay in FDA approval of the treatment.

The company also announced its intention to file a marketing authorization application for Arikayce with the European Medicines Agency by the end of this year.

The stock was down 25.91% to $12.78 at 3:12 p.m. More than 3.9 million shares changed hands, compared to the average volume of 883,698.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

INSM Chart INSM data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

North Korea Gives Wall Street Rude Awakening After Labor Day Break

North Korea Gives Wall Street Rude Awakening After Labor Day Break

Dow Tanks, Fear Gauge Spikes as United Tech Slumps, North Korea Rattles Nerves

Dow Tanks, Fear Gauge Spikes as United Tech Slumps, North Korea Rattles Nerves

North Korea Threat Roars Back Into Focus and Wall Street Retreats

North Korea Threat Roars Back Into Focus and Wall Street Retreats

Stock Futures Decline Amid Rising North Korea Tensions

Stock Futures Decline Amid Rising North Korea Tensions

Health Sector Down As Report of Industry Price Collusion Surfaces

Health Sector Down As Report of Industry Price Collusion Surfaces